Latest news from
CNX Therapeutics

On Saturday 16th September, a day blessed by the last of the beautiful summer weather, a pioneering team of employees – none of whom have ever previously competed in any kind of sporting event – bravely represented CNX at the Impetus Private Equity Triathlon! By participating in the triathlon CNX raised money for Impetus, an organisation what works to transform the lives of young people from disadvantaged backgrounds by making sure they get the right support to succeed in school, in work and in life.

What is Pre-eclampsia?  Pre-eclampsia is a pregnancy complication characterised by high blood pressure and signs of damage to organ systems, most often the liver and kidneys. It usually begins after 20 weeks of pregnancy and in women whose blood pressure had previously been normal. Although less common, pre-eclampsia can also occur four to six weeks […]

August has been a very exciting month for CNX; we have welcomed four new faces to the team! Our recent product acquisitions mean it’s vital to have a talented and dynamic team in in place as we expand our portfolio and work towards our goal of becoming a leading provider of critical medicines. Joining our […]

London, August 10th 2023 – CNX Therapeutics Limited (“CNX Therapeutics”), a speciality pharmaceutical company with a focus on improving access to medicines that are critical to the well-being of patients, is pleased to announce that it has successfully completed the acquisition of four cancer support products from Clinigen Limited (“Clinigen”), a global pharmaceutical services company. […]

What is Schizophrenia? Schizophrenia is a serious long-term mental health issue characterised by a profound disconnection from reality, known in medical terms as ‘psychosis’. Explained simply, it’s when sufferers have difficulty in telling what’s real and what’s not, often blurring the line between what’s real and what’s imagined. It affects how a person thinks, feels, […]

What is your perception of a Quality Management System? What comes to mind when you hear the words “Quality Assurance”? CNX Therapeutics is dedicated to our robust QMS that not only ensures customer satisfaction and regulatory compliance but also drives overall operational excellence, financial success, and long-term sustainability.

CNX Therapeutics is committed to having a positive impact on society, and we are proud to announce our first key milestone in our mission to take a pioneering approach to ESG; we are now participants to the UN Global Compact, a voluntary leadership platform for the development, implementation and disclosure of responsible business practices.

We are proud to announce that Sarah Morbey has joined CNX Therapeutics as Director of Legal Affairs & ESG. Sarah is a UK-qualified lawyer and company secretary, with almost 15 years of experience in the healthcare industry. Sarah joins CNX from McKesson where she was Lead Counsel within the MGPSL Business Unit, having previously held roles at Walgreens Boots Alliance and The Francis Crick Institute.

CNX Therapeutics is proud to announce that Ben Moore has joined CNX Therapeutics as our Vice President, Corporate Development.Ben has worked in the pharmaceutical industry for over 15 years and joins from Mundipharma International where he was Senior Director, Corporate and Business Development.

CNX Therapeutics is delighted to welcome Lee Debenham as our new Director of Scientific Affairs.Lee has worked in the pharmaceutical industry for 24 years and joins CNX from Bristol-Myers Squibb where he was Associate Director RCEE, and previously held roles at Celgene and Allergan.